KRAS mutations

GPTKB entity

Statements (58)
Predicate Object
gptkbp:instance_of gptkb:physicist
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:lung_adenocarcinoma
gptkb:biliary_tract_cancer
gptkbp:affects MAPK signaling pathway
P I3 K signaling pathway
gptkbp:are a subject of ongoing research
a subject of genetic counseling
common in cancer patients
a biomarker for therapy selection
a critical component of cancer biology
a focus of drug development
a focus of molecular diagnostics
a key factor in cancer research
a key player in oncogenesis
a major focus of translational research
a significant area of study in oncology
a target for immunotherapy
a target for novel drug development
important in personalized medicine
not present in all cancers
often studied in research
gptkbp:associated_with gptkb:healthcare_organization
metastasis
gptkbp:can_be inherited
linked to environmental factors
studied in animal models
detected in blood tests
studied for resistance mechanisms
analyzed by sequencing
analyzed for therapeutic implications
analyzed in liquid biopsies
associated with lifestyle factors
associated with patient outcomes
associated with specific clinical features
associated with specific mutations
linked to specific ethnic groups
monitored for treatment response
targeted by combination therapies
targeted for therapy
gptkbp:can_lead_to tumorigenesis
uncontrolled cell growth
gptkbp:exhibits heterogeneity
https://www.w3.org/2000/01/rdf-schema#label KRAS mutations
gptkbp:impact cell signaling pathways
gptkbp:influence tumor microenvironment
gptkbp:is_aimed_at specific therapies
gptkbp:is_found_in gptkb:healthcare_organization
gptkbp:is_involved_in GT Pase activity
nucleotide substitution
gptkbp:is_linked_to treatment resistance
gptkbp:is_often_depicted_as adenocarcinomas
gptkbp:is_often_used_in smokers
gptkbp:is_recognized_by tumor samples
gptkbp:is_studied_in clinical trials
gptkbp:recognizes biopsy
gptkbp:resulted_in poor prognosis
gptkbp:scientific_classification driver mutations